BioSpace News Archive

BioCapital

ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax’s (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL

Ascentage Pharma (6855.HK), today announced that it has released the updated results from a Phase Ib/II study of the Bcl-2 inhibitor lisaftoclax (APG-2575) in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) in a Poster Presentation at the 58th American Society of Clinical Oncology (ASCO) Annual Meeting.

June 7, 2022
·
8 min read
BioCapital

ASCO 2022 | Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC

Ascentage Pharma (6855.HK), today announced that it has released the results from its Phase I first-in-human (FIH) study of the company’s novel FAK inhibitor and third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) APG-2449.

June 7, 2022
·
8 min read
Business

NRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and Treasurer

NRx Pharmaceuticals, Inc. announced that the company’s Board of Directors appointed Seth Van Voorhees, Ph.D. as Chief Financial Officer and Treasurer effective June 13, 2022.

June 7, 2022
·
3 min read
Biotech Beach

NEURELIS PRESENTED CLINICAL DATA SUPPORTING SEIZURE CLUSTER INTERVAL ANALYSIS AT THE EPILEPSY FOUNDATION PIPELINE CONFERENCE

Neurelis, Inc., announced findings from a novel, investigational analysis of VALTOCO® (diazepam nasal spray) CIV.

June 7, 2022
·
7 min read
Drug Development

EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer

EpimAb Biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase Ib/II study in patients with non-small cell lung cancer (NSCLC) evaluating the combination of EMB-01, a bispecific antibody designed to simultaneously target EGFR and cMET on tumor cells, and Tagrisso® (osimertinib).

June 7, 2022
·
2 min read